Propranolol Hydrochloride Patent Expiration
Propranolol Hydrochloride is used for treating hemangioma, including infantile hemangioma. It was first introduced by Wyeth Pharmaceuticals Llc
Propranolol Hydrochloride Patents
Given below is the list of patents protecting Propranolol Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Hemangeol | US8338489 | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas | Oct 16, 2028 | Eton |
| Hemangeol | US8987262 | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas | Oct 16, 2028 | Eton |
| Innopran Xl | US6500454 | Timed, sustained release systems for propranolol |
Oct 04, 2021
(Expired) | Ani Pharms |
Propranolol Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Propranolol Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | Wake Forest University Health Sciences | NA |
TERMINATED
(Jul 1, 2026)
| PHASE2 |
| Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery | Roswell Park Cancer Institute | NA |
SUSPENDED
(Jul 1, 2026)
| PHASE1, PHASE2 |
| An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH | Tang-Du Hospital | NA |
NOT YET RECRUITING
(Apr 1, 2026)
| PHASE1 |